mTOR and cancer: insights into a complex relationship

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216

Upstream and downstream of mTOR

Hay, N., & Sonenberg, N. (2004) · Genes & Development · doi:10.1101/gad.1212704 · Cited by 4,181

TSC2 Mediates Cellular Energy Response to Control Cell Growth and Survival

Inoki, K., Zhu, T., & Guan, K.-L. (2003) · Cell · doi:10.1016/s0092-8674(03)00929-2 · Cited by 3,914

TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling

Inoki, K., Li, Y., Zhu, T., Wu, J., & Guan, K.-L. (2002) · Nature Cell Biology · doi:10.1038/ncb839 · Cited by 3,083

mTOR Interacts with Raptor to Form a Nutrient-Sensitive Complex that Signals to the Cell Growth Machinery

Kim, D., Sarbassov, D. D., Ali, S. M., King, J. E., Latek, R. R., Erdjument‐Bromage, H., Tempst, P., & Sabatini, D. M. (2002) · Cell · doi:10.1016/s0092-8674(02)00808-5 · Cited by 3,051

Rictor, a Novel Binding Partner of mTOR, Defines a Rapamycin-Insensitive and Raptor-Independent Pathway that Regulates the Cytoskeleton

Sarbassov, D. D., Ali, S. M., Kim, D.-H., Guertin, D. A., Latek, R. R., Erdjument-Bromage, H., Tempst, P., & Sabatini, D. M. (2004) · Current Biology · doi:10.1016/j.cub.2004.06.054 · Cited by 2,665

mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt

O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561

Prolonged Rapamycin Treatment Inhibits mTORC2 Assembly and Akt/PKB

Sarbassov, D. D., Ali, S. M., Sengupta, S., Sheen, J.-H., Hsu, P. P., Bagley, A. F., Markhard, A. L., & Sabatini, D. M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.03.029 · Cited by 2,365

Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive

Jacinto, E., Loewith, R., Schmidt, A., Lin, S., Rüegg, M. A., Hall, A., & Hall, M. N. (2004) · Nature Cell Biology · doi:10.1038/ncb1183 · Cited by 2,097

Two TOR Complexes, Only One of which Is Rapamycin Sensitive, Have Distinct Roles in Cell Growth Control

Loewith, R., Jacinto, E., Wullschleger, S., Lorberg, A., Crespo, J. L., Bonenfant, D., Oppliger, W., Jenoe, P., & Hall, M. N. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00636-6 · Cited by 1,886

Targeting stemness is an effective strategy to control EML4-ALK+ non-small cell lung cancer cells

Oh, S. J., Noh, K. H., Lee, Y. H., Hong, S.-O., Song, K., Lee, H.-J., Kim, S., Kim, T. M., Jeon, J., Seo, J. H., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5434 · Cited by 20

Structure-based optimization of morpholino-triazines as PI3K and mTOR inhibitors

Poulsen, A., Williams, M. R. V., Nagaraj, H., William, A. D., Wang, H., Soh, C. K., Xiong, Z. C., & Dymock, B. W. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.12.001 · Cited by 20

High expression of Golgi phosphoprotein-3 is associated with poor survival in patients with hepatocellular carcinoma

Hu, G., Li, Y.-Q., Yang, Y., Shi, W., Liao, A., Yao, Y., Zeng, B., & Yuan, J. (2014) · Tumor Biology · doi:10.1007/s13277-014-2105-8 · Cited by 20

Phase I study and preclinical efficacy evaluation of the mTOR inhibitor sirolimus plus gemcitabine in patients with advanced solid tumours

Martín-Liberal, J., Gil-Martín, M., Sáinz‐Jaspeado, M., Gonzalo, N., Rigo, R., Colom, H., Muñoz, C., Tirado, Ò. M., & del Muro, X. G. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.370 · Cited by 20

Targeting the PI3K/Akt/mTOR Pathway in Malignancy: Rationale and Clinical Outlook

Cho, D. (2014) · BioDrugs · doi:10.1007/s40259-014-0090-5 · Cited by 23

Antineoplastic effect of rapamycin is potentiated by inhibition of IRS-1 signaling in prostate cancer cells xenografts

de Oliveira, J. C., Souza, K. K., Dias, M. M., Faria, M. C., Ropelle, E. R., Flores, M. B. S., Ueno, M., Velloso, L. A., Saad, S. T. O., Saad, M. J. A., et al. (2008) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-008-0359-5 · Cited by 20

Phosphorylated mammalian target of rapamycin expression is associated with the response to chemoradiotherapy in patients with esophageal squamous cell carcinoma

Li, S.-H., Huang, E., Lu, H., Huang, W., Yen, C., Huang, W., & Chen, C. (2012) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2012.06.049 · Cited by 20

Elevated Poly-(ADP-Ribose)-Polymerase Activity Sensitizes Retinoblastoma-Deficient Cells to DNA Damage–Induced Necrosis

Liu, H., Knabb, J. R., Spike, B. T., & Macleod, K. F. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0439 · Cited by 20

mTOR inhibition sensitizes ONC201-induced anti-colorectal cancer cell activity

Jin, Z., Wang, W., Fang, D., & Jin, Y. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.08.126 · Cited by 20

mTOR activity and its prognostic significance in human colorectal carcinoma depending on C1 and C2 complex-related protein expression

Sticz, T. B., Molnár, A., Márk, Á., Hajdú, M., Nagy, N., Végső, G., Micsík, T., Kopper, L., & Sebestyén, A. R. (2016) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2016-203913 · Cited by 19

Discovery of simplified leucyladenylate sulfamates as novel leucyl-tRNA synthetase (LRS)-targeted mammalian target of rapamycin complex 1 (mTORC1) inhibitors

Yoon, S., Kim, J. H., Koh, Y., Tran, P.-T., Ann, J., Yoon, I., Jang, J., Kim, W. K., Lee, S., Lee, J., et al. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.06.002 · Cited by 15

miR‑144 suppresses proliferation and induces apoptosis of osteosarcoma cells via direct regulation of mTOR expression

Ren, Y., Zhang, T., Zhong, S., Zhao, Y., & Lv, Y. (2017) · Oncology Letters · doi:10.3892/ol.2017.7364 · Cited by 20

Immunology and Immunotherapeutic Approaches for Advanced Renal Cell Carcinoma: A Comprehensive Review

Hah, Y. S., & Koo, K. C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094452 · Cited by 21

iTRAQ-based quantitative phosphoproteomics provides insights into the metabolic and physiological responses of a carnivorous marine fish (Nibea albiflora) fed a linseed oil-rich diet

Qin, G., Xu, D., Lou, B., Chen, R., Wang, L., & Tan, P. (2020) · Journal of Proteomics · doi:10.1016/j.jprot.2020.103917 · Cited by 20

Striking the balance between PTEN and PDK1: it all depends on the cell context: Figure 1.Preprint

Iwanami, A., Cloughesy, T. F., & Mischel, P. S. (2009) · Genes & Development · doi:10.1101/gad.1832909 · Cited by 20

Cerebrospinal fluid as a liquid biopsy for molecular characterization of brain metastasis in patients with non-small cell lung cancer

Tsakonas, G., Tadigotla, V. R., Chakrabortty, S. K., Stragliotto, G., Chan, D., Lewensohn, R., Yu, W., Skog, J., Hydbring, P., & Ekman, S. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.107292 · Cited by 19

Significance of mammalian target of rapamycin in patients with locally advanced stage IV head and neck squamous cell carcinoma receiving induction chemotherapy with docetaxel, cisplatin, and fluorouracil

Li, S.-H., Lin, W., Huang, T., Chen, C., Chiu, T., Fang, F., Huang, W., Hsu, C., Luo, S., Lai, C., et al. (2015) · Head & Neck · doi:10.1002/hed.24111 · Cited by 19

Concurrent HDAC and mTORC1 Inhibition Attenuate Androgen Receptor and Hypoxia Signaling Associated with Alterations in MicroRNA Expression

Ellis, L., Lehet, K., Ramakrishnan, S., Adelaiye-Ogala, R. M., Miles, K. M., Wang, D., Liu, S., Atadja, P. W., Carducci, M. A., & Пили, Р. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027178 · Cited by 19

Rationale-based therapeutic combinations with PI3K inhibitors in cancer treatment

Castel, P., Toska, E., Zumsteg, Z. S., Carmona, F. J., Elkabets, M., Bosch, A., & Scaltriti, M. (2014) · Molecular & Cellular Oncology · doi:10.4161/23723548.2014.963447 · Cited by 22

Novel targets in esophageal and gastric cancer: beyond antiangiogenesis

Lee, W., Patel, J. H., & Lockhart, A. C. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903179286 · Cited by 19

Phosphorylation of Rictor at Thr1135 impairs the Rictor/Cullin-1 complex to ubiquitinate SGK1

Gao, D., Wan, L., & Wei, W. (2010) · Protein & Cell · doi:10.1007/s13238-010-0123-x · Cited by 19

The Antipancreatic Cancer Activity of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2

Chen, B., Xu, M., Zhang, H., Xu, M., Wang, X.-J., Tang, Q., & Tang, J. (2015) · DNA and Cell Biology · doi:10.1089/dna.2015.2886 · Cited by 19

Targeted Therapies for Solid Tumors

Stoffel, A. (2010) · BioDrugs · doi:10.2165/11535880-000000000-00000 · Cited by 19

Aerosolizable Marine Phycotoxins and Human Health Effects: In Vitro Support for the Biogenics Hypothesis

Acker, E. V., Rijcke, M. D., Asselman, J., Beck, I. M. E., Huysman, S., Vanhaecke, L., Schamphelaere, K. D., & Janssen, C. (2020) · Marine Drugs · doi:10.3390/md18010046 · Cited by 19

Dysregulation of translational control signaling in autism spectrum disorders

Hooshmandi, M., Wong, C., & Khoutorsky, A. (2020) · Cellular Signalling · doi:10.1016/j.cellsig.2020.109746 · Cited by 17

Renal Cell Carcinoma: Biological Features and Rationale for Molecular-targeted Therapy

Oya, M. (2009) · The Keio Journal of Medicine · doi:10.2302/kjm.58.1 · Cited by 19

Unveiling promising targets in gastric cancer therapy: A comprehensive review

Li, W., Wei, J., Cheng, M., & Liu, M. (2024) · Molecular Therapy Oncology · doi:10.1016/j.omton.2024.200857 · Cited by 21

Voies moléculaires dans le cancer du rein : de la biologie aux traitements de demain

Edeline, J., Vigneau, C. M., Patard, J., & Rioux-Leclercq, N. C. (2010) · Bulletin du Cancer · doi:10.1684/bdc.2010.1066 · Cited by 22

Dysregulation of mammalian target of rapamycin pathway in plasmacytoid variant of urothelial carcinoma of the urinary bladder

González-Roibón, N., Chaux, A., Al-Hussain, T. O., Osunkoya, A. O., Bezerra, S. M., Hicks, J. L., Epstein, J. I., & Netto, G. J. (2012) · Human Pathology · doi:10.1016/j.humpath.2012.07.009 · Cited by 18

Tracing cancer networks with phosphoproteomics

Solit, D. B., & Mellinghoff, I. K. (2010) · Nature Biotechnology · doi:10.1038/nbt1010-1028 · Cited by 18

Dual drug loaded vitamin D3 nanoparticle to target drug resistance in cancer

Palvai, S., Nagraj, J., Mapara, N., Chowdhury, R., & Basu, S. (2014) · RSC Advances · doi:10.1039/c4ra06475e · Cited by 18

Design, synthesis, cytotoxicity evaluation and docking studies of 1,2,4-triazine derivatives bearing different arylidene-hydrazinyl moieties as potential mTOR inhibitors

Khoshneviszadeh, M., Ranjbar, S., Edraki, N., Khoshneviszadeh, M., Foroumadi, A., & Miri, R. (2017) · Research in Pharmaceutical Sciences · doi:10.4103/1735-5362.220962 · Cited by 18

DNA polymerase gamma (Polγ) deficiency triggers a selective mTORC2 prosurvival autophagy response via mitochondria-mediated ROS signaling

Dhar, S. K., Bakthavatchalu, V., Dhar, B., Chen, J., Izumi, T., Zhu, H., Gao, T., & Clair, D. K. S. (2018) · Oncogene · doi:10.1038/s41388-018-0404-z · Cited by 18

Novel targeted therapies for metastatic breast cancer

Jazieh, K., Bell, R., Agarwal, N., & Abraham, J. (2020) · Annals of Translational Medicine · doi:10.21037/atm.2020.03.43 · Cited by 18

Therapeutic role of sirolimus in non-transplant kidney disease

Rangan, G. K., Nguyen, T., Mainra, R., Succar, L., Schwensen, K. G., Burgess, J. S., & Ho, K. O. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.03.014 · Cited by 17

mTOR complex 2 mediates Akt phosphorylation that requires PKCε in adult cardiac muscle cells

Moschella, P., McKillop, J. C., Pleasant, D. L., Harston, R. K., Balasubramanian, S., & Kuppuswamy, D. (2013) · Cellular Signalling · doi:10.1016/j.cellsig.2013.05.001 · Cited by 18

Growth Inhibition of Head and Neck Squamous Cell Carcinoma Cells by sgRNA Targeting the Cyclin D1 mRNA Based on TRUE Gene Silencing

Iizuka, S., Oridate, N., Nashimoto, M., Fukuda, S., & Tamura, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0114121 · Cited by 18

Everolimus in hormone receptor–positive advanced breast cancer: Targeting receptor-based mechanisms of resistance

Shtivelband, M. I. (2013) · The Breast · doi:10.1016/j.breast.2013.02.003 · Cited by 18

Discovery of (S)-4-isobutyloxazolidin-2-one as a novel leucyl-tRNA synthetase (LRS)-targeted mTORC1 inhibitor

Yoon, S., Kim, J. H., Yoon, I., Kim, C., Kim, S.-E., Koh, Y., Jeong, S. J., Lee, J., Kim, S., & Lee, J. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.05.011 · Cited by 19

Eukaryotic initiation factor 4E is a novel effector of mTORC1 signaling pathway in cross talk with Mnk1

Batool, A., Majeed, S. T., Aashaq, S., Majeed, R., Bhat, N. N., & Andrabi, K. I. (2019) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-019-03663-z · Cited by 18

Ras Homolog Enriched in the Brain is Linked to Retinal Ganglion Cell Apoptosis after Light Injury in Rats

Shu, Q., Xu, Y., Zhuang, H., Fan, J., Sun, Z., Zhang, M., & Xu, G. (2014) · Journal of Molecular Neuroscience · doi:10.1007/s12031-014-0281-z · Cited by 17

A case study of an integrative genomic and experimental therapeutic approach for rare tumors: identification of vulnerabilities in a pediatric poorly differentiated carcinoma

Cruz, F. S. D., Diolaiti, D., Turk, A. T., Rainey, A. R., Ambesi‐Impiombato, A., Andrews, S. J., MANSUKHANI, M. M., Nagy, P. L., Alvarez, M. J., Califano, A., et al. (2016) · Genome Medicine · doi:10.1186/s13073-016-0366-0 · Cited by 18

mTOR as an eligible molecular target for possible pharmacological treatment of nonalcoholic steatohepatitis

Arora, M., Canová, N. K., & Farghali, H. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.174857 · Cited by 17

PI3K/AKT/mTOR signaling pathway modulation by circular RNAs in breast cancer progression

Fath, M. K., Masouleh, R. A., Afifi, N., Loghmani, S., Tamimi, P., Fazeli, A., Mousavian, S. A., Falsafi, M. M., & Barati, G. (2022) · Pathology - Research and Practice · doi:10.1016/j.prp.2022.154279 · Cited by 17

Direct regulation of FNIP1 and FNIP2 by MEF2 sustains MTORC1 activation and tumor progression in pancreatic cancer

Li, X., Nie, T., Lu, F., Huang, L. H., Shi, X., Ren, D., Lu, J., Li, X., Xu, T., Cui, B., et al. (2023) · Autophagy · doi:10.1080/15548627.2023.2259735 · Cited by 17

An Overview of Renal Cell Carcinoma Hallmarks, Drug Resistance, and Adjuvant Therapies

PRADE, J. D. S., SOUZA, R. S. D., D’ÁVILA, C. M. D. S., SILVA, T. C. D., LIVINALLI, I. C., Bertoncelli, A. C. Z., SACCOL, F. K., Mendes, T. D. O., WENNING, L. G., Salles, T. D. R., et al. (2023) · Cancer Diagnosis & Prognosis · doi:10.21873/cdp.10264 · Cited by 19

Engineering metabolism to modulate immunity

Kapnick, S. M., Martin, C. A., & Jewell, C. M. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.115122 · Cited by 18

Multigene targeting of signal transduction pathways for the treatment of breast and prostate tumors

Rubenstein, M., Tsui, P. T., & Guinan, P. (2008) · Medical Oncology · doi:10.1007/s12032-008-9088-5 · Cited by 17

Human T cell expansion and experimental autoimmune encephalomyelitis inhibited by Lenaldekar, a small molecule discovered in a zebrafish screen

Cusick, M. F., Libbey, J. E., Trede, N. S., Eckels, D. D., & Fujinami, R. S. (2012) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2011.12.024 · Cited by 17

Risk of hematologic toxicities in patients with solid tumors treated with everolimus: A systematic review and meta-analysis

Funakoshi, T., Latif, A., & Galsky, M. D. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.06.001 · Cited by 17

Molecular targeted therapies in the treatment of gastroenteropancreatic neuroendocrine tumors

Capdevila, J., & Salazar, R. (2009) · Targeted Oncology · doi:10.1007/s11523-009-0128-7 · Cited by 17

Targeting mTOR and p53 Signaling Inhibits Muscle Invasive Bladder Cancer In Vivo

Madka, V., Mohammed, A., Li, Q., Zhang, Y., Biddick, L., Patlolla, J. M. R., Lightfoot, S. A., Towner, R. A., Wu, X., Steele, V. E., et al. (2015) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-15-0199 · Cited by 17

The Scribble–Dlg–Lgl Module in Cell Polarity Regulation

Humbert, P. O., Russell, S. M., Smith, L. K., & Richardson, H. E. (2015) · Springer eBooks · doi:10.1007/978-3-319-14463-4_4 · Cited by 17

Physical Activity, Dietary Calorie Restriction, and Cancer

McTiernan, A. (2010) · Springer eBooks · doi:10.1007/978-1-4419-7551-5 · Cited by 17

The mTOR Kinase Inhibitor CZ415 Inhibits Human Papillary Thyroid Carcinoma Cell Growth

Li, X., Li, Z., Song, Y., Liu, W., & Liu, Z. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000488625 · Cited by 17

Everolimus enhances TRAIL‐mediated anti‐tumor activity of liver resident natural killer cells in mice

Saparbay, J., Tanaka, Y., Tanimine, N., Ohira, M., & Ohdan, H. (2019) · Transplant International · doi:10.1111/tri.13536 · Cited by 17

Genomic variation as a marker of response to neoadjuvant therapy in locally advanced rectal cancer

Douglas, J. K., Callahan, R. E., Hothem, Z. A., Cousineau, C. S., Kawak, S., Thibodeau, B. J., Bergeron, S., Li, W., Peeples, C., & Wasvary, H. J. (2020) · Molecular & Cellular Oncology · doi:10.1080/23723556.2020.1716618 · Cited by 17

Discovery of Leucyladenylate Sulfamates as Novel Leucyl-tRNA Synthetase (LRS)-Targeted Mammalian Target of Rapamycin Complex 1 (mTORC1) Inhibitors

Yoon, S., Kim, J. H., Kim, S.-E., Kim, C., Tran, P.-T., Ann, J., Koh, Y., Jang, J., Kim, S., Moon, H.-S., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01190 · Cited by 17

White spot syndrome virus directly activates mTORC1 signaling to facilitate its replication via polymeric immunoglobulin receptor-mediated infection in shrimp

Hong, P.-P., Li, C., Niu, G.-J., Zhao, X., & Wang, J. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1010808 · Cited by 17

Activation of mTORC1 Signaling Pathway in AIDS-Related Lymphomas

El-Salem, M., Raghunath, P. N., Marzec, M., Liu, X., Kasprzycka, M., Robertson, E. S., & Wasik, M. A. (2009) · American Journal Of Pathology · doi:10.2353/ajpath.2009.080451 · Cited by 17

Dysregulation of the mTOR Pathway Secondary to Mutations or a Hostile Microenvironment Contributes to Cancer and Poor Wound Healing

Clark, R. A. F., & Pavlis, M. (2009) · Journal of Investigative Dermatology · doi:10.1038/jid.2008.441 · Cited by 17

Small-molecule inhibitors of SREBP activation – potential for new treatment of metabolic disorders

Watanabe, M., & Uesugi, M. (2013) · MedChemComm · doi:10.1039/c3md00177f · Cited by 18

ATP-site binding inhibitor effectively targets mTORC1 and mTORC2 complexes in glioblastoma

Neil, J. A., Shannon, C. M., MOHAN, A. L., Laurent, D., Murali, R., & Jhanwar‐Uniyal, M. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3311 · Cited by 18

Protor-2 interacts with tristetraprolin to regulate mRNA stability during stress

Holmes, B., Artinian, N., Anderson, L., Martin, J., Masri, J., Cloninger, C., Bernath, A., Bashir, T., Benavides-Serrato, A., & Gera, J. (2011) · Cellular Signalling · doi:10.1016/j.cellsig.2011.09.015 · Cited by 17

Targeting mTOR and eIF4E: a feasible scenario in ovarian cancer therapy

Romagnoli, A., Maracci, C., D’Agostino, M., Teana, A. L., & Marino, D. D. (2021) · Cancer Drug Resistance · doi:10.20517/cdr.2021.20 · Cited by 18

Molecular Pathways in Prolactinomas: Translational and Therapeutic Implications

Biagetti, B., & Simó, R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222011247 · Cited by 18

Marcromolecular Architecture and Encapsulation of the Anticancer Drug Everolimus Control the Self-Assembly of Amphiphilic Polypeptide-Containing Hybrids

Karatzas, A., Haataja, J. S., Skoulas, D., Bilalis, P., Varlas, S., Apostolidi, P., Sofianopoulou, S., Stratikos, E., Houbenov, N., Ikkala, O. T., et al. (2019) · Biomacromolecules · doi:10.1021/acs.biomac.9b01331 · Cited by 16

Regulation of Cell Signaling Pathways and Non-Coding RNAs by Baicalein in Different Cancers

Farooqı, A. A., Kapanova, G. Z., Kalmakhanov, S. B., Tanbayeva, G., Zhakipbekov, K. S., Rakhmetova, V. S., & Syzdykbayev, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158377 · Cited by 16

Mechanisms of Endocrine Resistance in Hormone Receptor-Positive Breast Cancer

Marra, A., Trapani, D., Ferraro, E., & Curigliano, G. (2023) · Cancer treatment and research · doi:10.1007/978-3-031-33602-7_9 · Cited by 16

Management of Metastatic Renal Cell Carcinoma Progressed After Sunitinib or Another Antiangiogenic Treatment

Iacovelli, R., Palazzo, A., Trenta, P., Mezi, S., Pellegrino, D., Naso, G., & Cortesi, E. (2013) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e31827de888 · Cited by 16

Targeting mtor-Dependent Tumours with Specific Inhibitors: A Model for Personalized Medicine based on Molecular Diagnoses

Furic, L., Livingstone, M., Dowling, R. J. O., & Sonenberg, N. (2009) · Current Oncology · doi:10.3747/co.v16i1.406 · Cited by 16

A Chemical Genetic Screen for mTOR Pathway Inhibitors Based on 4E-BP-Dependent Nuclear Accumulation of eIF4E

Livingstone, M., Larsson, O. S., Sukarieh, R., Pelletier, J., & Sonenberg, N. (2009) · Chemistry & Biology · doi:10.1016/j.chembiol.2009.11.010 · Cited by 16

Everolimus and mTOR inhibition in pancreatic neuroendocrine tumors

Yim, K.-L. (2012) · Cancer Management and Research · doi:10.2147/cmar.s25979 · Cited by 16

Survival of salivary gland cancer stem cells requires mTOR signaling

de Andrade, N. P., Warner, K. A., Zhang, Z., Pearson, A. T., Mantesso, A., Guimarães, D. M., ALTEMANI, A. M. D. A. M., Mariano, F. V., Nunes, F. D., & Nor, J. E. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03391-7 · Cited by 16

Modulation of mTOR and epigenetic pathways as therapeutics in gallbladder cancer

Yang, D., Chen, T., Zhan, M., Xu, S., Yin, X., Liu, Q., Chen, W., Zhang, Y., Liu, D., Yan, J., et al. (2020) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2020.11.007 · Cited by 16

Hepatotoxicity of Immunosuppressive Drugs

Reuben, A. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-387817-5.00031-5 · Cited by 17

Rictor/mammalian target of rapamycin 2 regulates the development of notch1 induced murine T-cell acute lymphoblastic leukemia via forkhead box O3

Hua, C., Guo, H., Bu, J., Zhou, M., Cheng, H., He, F., Wang, J., Wang, X., Zhang, Y., Wang, Q., et al. (2014) · Experimental Hematology · doi:10.1016/j.exphem.2014.08.006 · Cited by 16

The rationale for mTOR inhibition in epithelial ovarian cancer

Trinh, X. B., van Dam, P. A., Dirix, L. Y., Vermeulen, P. B., & Tjalma, W. A. A. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903321508 · Cited by 16

Emerging therapeutic targets for the treatment of human acute myeloid leukemia (part 1) – gene transcription, cell cycle regulation, metabolism and intercellular communication

Reikvam, H., Hauge, M., Brenner, A. K., Hatfield, K. J., & Bruserud, Ø. (2015) · Expert Review of Hematology · doi:10.1586/17474086.2015.1032935 · Cited by 16

Dual-Blocking of PI3K and mTOR Improves Chemotherapeutic Effects on SW620 Human Colorectal Cancer Stem Cells by Inducing Differentiation

Kim, M.-J., Koo, J.-E., Han, G.-Y., Kim, B., Lee, Y.-S., Ahn, C., & Kim, C. (2016) · Journal of Korean Medical Science · doi:10.3346/jkms.2016.31.3.360 · Cited by 16

Nanosecond Pulsed Electric Fields Enhance the Anti-tumour Effects of the mTOR Inhibitor Everolimus against Melanoma

Dai, J., Wu, S., Kong, Y., Chi, Z., Si, L., Sheng, X., Cui, C., Fang, J., Zhang, J., & Guo, J. (2017) · Scientific Reports · doi:10.1038/srep39597 · Cited by 16

Diverse Immunoprofile of Ductal Adenocarcinoma of the Prostate with an Emphasis on the Prognostic Factors

Jeong, S. U., Kashikar, A., Park, J.-M., Han, M., Hwang, H. S., Jeong, H. J., Go, H., & Cho, Y. M. (2017) · Journal of Pathology and Translational Medicine · doi:10.4132/jptm.2017.06.02 · Cited by 16

Prognostic significance and function of mammalian target of rapamycin in tongue squamous cell carcinoma

Li, S.-H., Chien, C., Huang, W., Luo, S., Su, Y.-Y., Tien, W.-Y., Lan, Y.-C., & Chen, C. (2017) · Scientific Reports · doi:10.1038/s41598-017-08345-8 · Cited by 16

Rapamycin rescues BMP mediated midline craniosynostosis phenotype through reduction of mTOR signaling in a mouse model

Kramer, K., Yang, J., Swanson, W. B., Hayano, S., Toda, M., Pan, H., Kim, J. K., Krebsbach, P. H., & Mishina, Y. M. (2018) · genesis · doi:10.1002/dvg.23220 · Cited by 17

Hepatocellular Carcinoma: Molecular and Genomic Guideline for the Clinician

Frenette, C. T., & Gish, R. G. (2011) · Clinics in Liver Disease · doi:10.1016/j.cld.2011.03.010 · Cited by 16

Advances in Research on the Effectiveness and Mechanism of Active Ingredients from Traditional Chinese Medicine in Regulating Hepatic Stellate Cells Autophagy Against Hepatic Fibrosis

Liu, X., Zhang, W., Ma, B.-F., Sun, M., & Shang, Q.-H. (2024) · Drug Design Development and Therapy · doi:10.2147/dddt.s467480 · Cited by 16

Combining PI3K/Akt/mTOR Inhibition With Chemotherapy

Vera, A. A. D., & Reznik, S. E. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816435-8.00014-6 · Cited by 15

The role and implication of autophagy in cholangiocarcinoma

Khizar, H., Hu, Y., Wu, Y., & Yang, J. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01631-7 · Cited by 16

A Comprehensive Review on Targeted Cancer Therapy: New Face of Treatment Approach

Karati, D., & Kumar, D. (2023) · Current Pharmaceutical Design · doi:10.2174/0113816128272203231121034814 · Cited by 15

Dual mTORC1/2 inhibition by INK-128 results in antitumor activity in preclinical models of osteosarcoma

Jiang, H., & Zeng, Z. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.10.119 · Cited by 15

Effects of metformin on fertilisation of bovine oocytes and early embryo development: possible involvement of AMPK3-mediated TSC2 activation

Pikiou, O., Vasilaki, A., Leondaritis, G., Vamvakopoulos, N. C., & Messinis, I. E. (2013) · Zygote · doi:10.1017/s0967199413000300 · Cited by 15

Targeted Agents in Preclinical and Early Clinical Development for the Treatment of Cancer Bone Metastases

Hiraga, T. (2016) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2016.1142972 · Cited by 15

microRNA-19a protects osteoblasts from dexamethasone via targeting TSC1

Liu, G., Chen, F., Ji, F., Fei, H., Xie, Y., & Wang, S. (2017) · Oncotarget · doi:10.18632/oncotarget.23326 · Cited by 15

The activation of lactate dehydrogenase induced by mTOR drives neoplastic change in breast epithelial cells

Manerba, M., Ianni, L. D., Govoni, M., Comparone, A., & Stefano, G. D. (2018) · PLoS ONE · doi:10.1371/journal.pone.0202588 · Cited by 15

Blockage of glutamine-dependent anaplerosis affects mTORC1/2 activity and ultimately leads to cellular senescence-like response

Liao, G.-Y., Lee, M., Fan, J.-J., Hsiao, P., Lee, C.-S., Su, S.-Y., Hwang, J.-J., & Ke, F. (2019) · Biology Open · doi:10.1242/bio.038257 · Cited by 18

VicTORia: a randomised phase II study to compare vinorelbine in combination with the mTOR inhibitor everolimus versus vinorelbine monotherapy for second-line chemotherapy in advanced HER2-negative breast cancer

Decker, T. W., Marschner, N. W., Muendlein, A., Welt, A., Hagen, V. A., Rauh, J., Schröder, H., Jaehnig, P., Potthoff, K., & Lerchenmuller, C. A. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-019-05280-2 · Cited by 15

Putative role of the mTOR/4E-BP1 signaling pathway in the carcinogenesis and progression of gastric cardiac adenocarcinoma

Yang, H., Li, X., Xing, L., Wang, J., WANG, J. L., Xia, Y., & Zhang, X. (2012) · Molecular Medicine Reports · doi:10.3892/mmr.2012.1208 · Cited by 15

Intermittent hypoxia training after C2 hemisection modifies the expression of PTEN and mTOR

Gutierrez, D. V., Clark, M., Nwanna, O., & Alilain, W. J. (2013) · Experimental Neurology · doi:10.1016/j.expneurol.2013.05.013 · Cited by 15

SERPINB3 is associated with longer survival in transgenic mice

Villano, G., Ruvoletto, M., Ceolotto, G., Quarta, S., Calabrese, F., Turato, C., Tono, N., Crescenzi, M., Biasiolo, A., Cattelan, A. M., et al. (2013) · Scientific Reports · doi:10.1038/srep03056 · Cited by 15

Drug discovery targeting the mTOR pathway

Martelli, A. M., Buontempo, F., & McCubrey, J. A. (2018) · Clinical Science · doi:10.1042/cs20171158 · Cited by 77

TOR (target of rapamycin) as an anti-cancer target

Bousquet, G., Dreyer, C., Faivre, S. J., & Raymond, É. (2007) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2008.04.004 · Cited by 2

Mammalian Target of Rapamycin (mTOR) Signalling Pathway-A Potential Target for Cancer Intervention: A Short Overview

Basnet, R., Basnet, B. B., Gupta, R., Basnet, T. B., Khadka, S., & Alam, M. S. (2023) · Current Molecular Pharmacology · doi:10.2174/1874467217666230331081959 · Cited by 11

Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy

Wander, S. A., Hennessy, B. T., & Slingerland, J. M. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44145 · Cited by 427

Unveiling the Role of Mechanistic Target of Rapamycin Kinase (MTOR) Signaling in Cancer Progression and the Emergence of MTOR Inhibitors as Therapeutic Strategies

Mehta, D., Rajput, K., Jain, D., Bajaj, A., & Dasgupta, U. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00530 · Cited by 25